When was Renalys founded?

Renalys was founded in 2023 and raised its 1st funding round 1 year after it was founded.

Where is Renalys located?

Renalys is headquartered in Chuo City, Japan.

Who is the current CEO of Renalys?

BT Slingsby of Renalys. They have also founded 1 company.

Is Renalys a funded company?

Renalys is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jul 17, 2024.

When was the latest funding round of Renalys?

Renalys' latest funding was a $***** Series A round on Jul 17, 2024, with participation from 6 investors. Its primary sector is Nephrology. Globally, the Nephrology sector has seen $256M in funding in 2026 to date.

Where does Renalys rank among its competitors?

Renalys ranks 6th amongst 117 active competitors, of which 38 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Renalys?

Renalys' top competitors include Akebia Therapeutics, Ardelyx and Alchemab. Among them, Alchemab secured the most recent funding round in July, 2026.

Renalys - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for the treatment of renal diseases. The company has launched sparsentan an oral Dual Endothelin Angiotensin Receptor Antagonist (DEARA), for the treatment of IgA Nephropathy (IgAN).

Website: renalys.com
Part Of

Key Metrics

Founded Year

2023

Location

Chuo City, Japan

Stage

Acquired

Total Funding

$38.2M in 1 round

Latest Funding Round

Series A, Jul 17, 2024, $*****

Investors

SR One & 5 more

Ranked

6^th among 117 active competitors

Similar Companies

Akebia Therapeutics & 130 more

Exit Details

Acquired by Chugai Pharmaceutical (Oct 24, 2025)

View Renalys' full profile

Renalys is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Renalys Pharma, Inc. CIN: 010401173611 , Japan, Active	Jan 01, 2023	-	-	-

Renalys got acquired by Chugai Pharmaceutical on Oct 24, 2025 at an acquisition amount of $*****.

Click here to take a look at Renalys's acquisition in detail

Renalys has raised a total funding of $38.2M over 1 round. Its latest funding round was a Series A round on Jul 17, 2024 for $*****. 6 investors participated in its latest round. Renalys has 6 institutional investors.

Here is the list of recent funding rounds of Renalys:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 17, 2024	2371477	Series A	3535350	2207854	1914940	6250104

Access funding benchmarks and valuations. Sign up today!

View details of Renalys's funding rounds and investors

The founders of Renalys are BT Slingsby and Takeshi Takahashi. BT Slingsby is the CEO of Renalys.

Here are the details of Renalys' key team members:

BT Slingsby: Co-Founder & CEO of Renalys. They serve on the board of 1 company.
Takeshi Takahashi: Co-Founder of Renalys. They serve on the board of 1 company.

Renalys' Board of Directors

Renalys's board has 4 active members. BT Slingsby and Takeshi Takahashi are part of team and Hanai Chen and Rajeev Dadoo are independent board members.

Here is the list of Renalys' board of directors:

Name	Type	Representing	Status	Duration
BT Slingsby	Team	-	Current	6y 4m
Takeshi Takahashi	Team	-	Current	6y 4m
Hanai Chen	Independent board member	-	Current	5y 8m
z{ibspl	Independent board member	-	Current	1y 6m

View details of Renalys's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Renalys include Akebia Therapeutics, Ardelyx and Alchemab. Here is the list of Top 10 competitors of Renalys, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Longitude Capital & 13 others	66/100
2nd	Ardelyx 2007, Fremont (United States), Public	Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases	$61.1M	Amgen Business Development, New Enterprise Associates ... & 11 others	65/100
3rd	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
4th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	VenBio, Redmile Group & 10 others	64/100
5th	Alebund 2018, Shanghai (China), Public	Developer of therapeutics for kidney diseases	$114M	Morningside, 3H Health Investment & 14 others	63/100
6th	Renalys 2023, Chuo City (Japan), Acquired	Developer of therapeutics for the treatment of renal diseases	$38.2M	JP Investment, Sumitomo Mitsui Trust Bank ... & 4 others	61/100
7th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	60/100
8th	Secretome Therapeutics 2018, Dallas (United States), Series A	Developer of cell-based therapies for multiple diseases	$52.2M	RA Capital Management, Parent Project Muscular Dystrophy ... & 2 others	60/100
9th	Arthrosi Therapeutics 2017, Irvine (United States), Acquired	Developer of therapeutics for gout, chronic kidney diseases, and oncology	$293M	Prime Eight Capital, Guangrun Health Industry ... & 11 others	60/100
10th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	59/100